EARLY ONSET OF ANTIPRURITIC EFFECTS WITH SERLOPITANT FOR CHRONIC PRURITUS: POST HOC ANALYSIS RESULTS FROM A RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL

被引：0
|
作者：
Staender, Sonja [1 ]
Yosipovitch, Gil [2 ]
Hirman, Joe [3 ]
Kwon, Paul [4 ]
机构：
[1] Univ Hosp Munster, Dept Dermatol, Ctr Chron Pruritus, Munster, Germany
[2] Univ Miami, Sch Med, Dept Dermatol, Miami Itch Ctr, Miami, FL 33152 USA
[3] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[4] Menlo Therapeut Inc, Menlo Pk, CA USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2017年 / 97卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
PP79
引用
收藏
页码：1058 / 1058
页数：1
相关论文
共 50 条
  • [21] Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial
    Elkins, Jacob
    Elkind, Mitchell
    Veltkamp, Roland
    Montaner, Joan
    Johnston, S.
    Singhal, Aneesh
    Becker, Kyra
    Lansberg, Maarten
    Chang, Ih
    Tang, Weihua
    Gheuens, Sarah
    Mehta, Lahar
    NEUROLOGY, 2016, 86
  • [22] Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial
    Elkins, Jacob
    Elkind, Mitchell
    Veltkamp, Roland
    Montanera, Joan
    Johnston, S.
    Singhal, Aneesh
    Becker, Kyra
    Lansberg, Maarten
    Chang, Ih
    Tang, Weihua
    Gheuens, Sarah
    Mehta, Lahar
    NEUROLOGY, 2016, 86
  • [23] Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial
    Elkins, Jacob
    Elkind, Mitchell
    Veltkamp, Roland
    Montaner, Joan
    Johnston, S.
    Singhal, Aneesh
    Becker, Kyra
    Lansberg, Maarten
    Chang, Ih
    Tang, Weihua
    Gheuens, Sarah
    Mehta, Lahar
    NEUROLOGY, 2016, 86
  • [24] Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial
    Elkins, Jacob
    Elkind, Mitchell
    Veltkamp, Roland
    Montaner, Joan
    Johnston, S.
    Singhal, Aneesh
    Becker, Kyra
    Lansberg, Maarten
    Chang, Ih
    Tang, Weihua
    Gheuens, Sarah
    Mehta, Lahar
    NEUROLOGY, 2016, 86
  • [25] Randomized, Placebo-Controlled Trial or Post Hoc Subgroup Analysis: The Importance of Standardized and Comprehensive Reporting Reply
    Hatano, Hiroyu
    Bacchetti, Peter
    Hsue, Priscilla Y.
    Deeks, Steven G.
    JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (01): : 159 - 160
  • [26] Responder Rates to Atogepant in Patients With Episodic Migraine: A Post Hoc Analysis of Results From a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Dodick, David W.
    Ailani, Jessica
    Goadsby, Peter J.
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Li, Ye
    Szegedi, Armin
    CEPHALALGIA, 2019, 39 : 183 - 184
  • [27] Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Dodick, D. W.
    Ailani, J.
    Goadsby, P. J.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Li, Y.
    Szegedi, A.
    HEADACHE, 2019, 59 : 79 - 80
  • [28] Results of the Tokyo Trial of Prevention of Post-ERCP Pancreatitis with Risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial
    Uchino, Rie
    Isayama, Hiroyuki
    Tsujino, Takeshi
    Sasahira, Naoki
    Ito, Yukiko
    Matsubara, Saburo
    Takahara, Naminatsu
    Arizumi, Toshihiko
    Toda, Nobuo
    Mohri, Dai
    Togawa, Osamu
    Yagioka, Hiroshi
    Yanagihara, Yoshitsugu
    Nakajima, Katsuyoshi
    Akiyama, Dai
    Hamada, Tsuyoshi
    Miyabayashi, Koji
    Mizuno, Suguru
    Kawakubo, Kazumichi
    Kogure, Hirofumi
    Sasaki, Takashi
    Yamamoto, Natsuyo
    Nakai, Yousuke
    Hirano, Kenji
    Tada, Minoru
    Koike, Kazuhiko
    GASTROINTESTINAL ENDOSCOPY, 2013, 78 (06) : 842 - 850
  • [29] α-Galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial
    Woltman, Andrea M.
    ter Borg, Martijn J.
    Binda, Rekha S.
    Sprengers, Dave
    von Blomberg, B. Mary E.
    Scheper, Rik J.
    Hayashi, Kunihiko
    Nishi, Nobusuke
    Boonstra, Andre
    von der Molen, Renate
    Janssen, Harry L. A.
    ANTIVIRAL THERAPY, 2009, 14 (06) : 809 - 818
  • [30] OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
    Diener, H. C.
    Dodick, D. W.
    Aurora, S. K.
    Turkel, C. C.
    DeGryse, R. E.
    Lipton, R. B.
    Silberstein, S. D.
    Brin, M. F.
    CEPHALALGIA, 2010, 30 (07) : 804 - 814
12345